AngioScore Files Patent Infringement Suit Against TriReme Medical and Quattro
FREMONT, Calif.--(BUSINESS WIRE)--AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today filed suit against TriReme Medical, Inc. (“TriReme”) and Quattro Vascular Pte Ltd (“Quattro”)for infringement of United States Patents Nos. 7,691,119 and 7,931,663 which cover specialized angioplasty balloon catheters and their use.
“The intellectual property of AngioScore is very important to the Company and we believe that our intellectual property should be respected. We are obligated to our shareholders to enforce our patent rights when we believe those rights have been infringed.”
The suit is directed at an angioplasty balloon catheter sold under the name “Chocolate” by TriReme and Quattro. The Chocolate products compete directly with AngioScore’s AngioSculpt Scoring Balloon Catheter. Quattro is located in Singapore and is a subsidiary of TriReme, which is located in Pleasanton, California.
Thomas Trotter, CEO of AngioScore, said “The intellectual property of AngioScore is very important to the Company and we believe that our intellectual property should be respected. We are obligated to our shareholders to enforce our patent rights when we believe those rights have been infringed.”
The AngioSculpt Scoring Balloon Catheters represent the next generation in angioplasty catheters for both coronary and peripheral artery disease. Their innovative nitinol elements provide unique circumferential scoring of plaque, leading to precise and predictable luminal enlargement across a wide range of lesion types while avoiding “geographic miss” through their unique anti-slippage properties. The AngioSculpt catheters provide the versatility and effectiveness of a new technology together with the simplicity and deliverability of traditional high-performance balloon catheters.
AngioSculpt catheters have now been used in more than 200,000 procedures worldwide and have achieved an outstanding safety and performance record in the treatment of both coronary and peripheral artery disease.